Developer docs
API playgroundTry for free, no card

Search company profiles

Fluence

Full company profile

uuid00025dz

Namestring
Fluence
Legal namestring
Fluence International, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Fluence operates an e-learning platform that delivers professional certificate programs in psychedelic-assisted therapy and integration for licensed mental health clinicians, alongside continuing education webinars and an introductory on-demand course for non-clinicians. The product architecture centers on a required 22-hour core curriculum, "Essentials of Psychedelic Therapy," that unlocks three specialty professional certificates covering Psychedelic Harm Reduction and Integration Therapy, Ketamine-Assisted Psychotherapy, and Psilocybin Facilitation, each carrying CE credits approved by the APA, ASWB, and NYSED. Fluence wraps the curriculum in proprietary infrastructure including a custom learning management system with role-based access and timestamped training tracking, a digital badging system, and the Psychedelic Therapist Directory, which functions as a marketplace connecting certified graduates with prospective clients and industry partners.

Fluence generates revenue through two distinct streams: individual clinician course sales (multi-year subscription pricing for the core and certificate programs, pay-as-you-go webinars and introductory content, and a 20% bundle discount) and B2B clinical trial training services sold to pharmaceutical and biotech drug developers. The B2B line includes protocol design consultation, treatment manual development, adherence criteria creation, multinational trial support, and the company's AI-powered training platform that uses generative AI to score role-play transcripts against custom rubrics and produce structured feedback. The AI capability is a key differentiator: it has been adopted by named drug developers including Reunion Neuroscience, Cybin, and Tryp Therapeutics, and is built on training data accumulated across over a dozen developer engagements, multiple compounds, and multilingual multinational trial contexts. The company also offers post-launch commercialization support covering clinician training, clinic staff training, and patient education materials.

The company is privately held, headquartered in the Bronx, New York, led by CEO and Co-Founder Elizabeth Nielson, PhD, and has trained over 8,000 therapists cumulatively. It has raised approximately $3 million across a November 2021 seed round ($1.6M from JLS Fund, Palo Santo, and Neo Kuma Ventures) and a February 2022 follow-on ($1.4M). Revenue is not publicly disclosed, but the combination of an 11-50 person headcount, a distributed individual learner base, and a small but growing enterprise B2B book places estimated annual revenue in the low single-digit millions. Strategic positioning centers on being the preeminent credentialing and training infrastructure for both the emerging psychedelic clinician workforce and the drug developers commercializing psychedelic-based treatments.

Short descriptiontext

Fluence is a New York-based e-learning platform that provides APA/ASWB/NYSED-accredited professional certificates in psychedelic-assisted therapy to licensed clinicians, plus AI-powered clinical trial training and consultation services to drug developers. The company has trained over 8,000 therapists and serves a global client base.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic therapy training, professional certificate programs, continuing education credits, clinical trial training, therapist directory platform
Industry1 code
PRIMARYEDAGANAJ
Healthcare & Clinical Professional Development (CME/CE)
Education/Educational Publishing & Learning Content/Professional Development & Training Materials
NAICS code1 code
  • Professional and Management Development Training61143
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Professional Training and Continuing Education
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Professional Certification Courses
TypeSubscription Recurring
Description

Fluence offers professional certification programs in psychedelic therapy areas including Psychedelic Harm Reduction and Integration Therapy, Ketamine-Assisted Psychotherapy, and Psilocybin Facilitation. All programs include CE credits for psychologists, social workers, and mental health counselors as part of the base price.

fluencetraining.com
2B2B Clinical Trial Training Services
TypeProfessional Services
Description

Consultation and custom training programs for drug developers including protocol design, treatment manual creation, adherence criteria development, and multinational trial support. Services include custom LMS, mobile apps, content libraries, and differentiated training tracks.

fluencetraining.com
3AI-Enabled Training Tools
TypeSubscription Recurring
Description

AI-powered feedback tools for clinical trial training that analyze role-play transcripts and provide automated adherence scoring, offered to drug development partners.

fluencetraining.com
4Webinars and Continuing Education
TypeOne Time License
Description

Live-online webinars offering CE credits for clinicians, covering topics in psychedelic therapy, legislation, practice building, and specialized clinical applications.

fluencetraining.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details4 tiers
1Essentials of Psychedelic Therapy - Core Curriculum
ModelSubscriptionBilling cadenceMulti-year contract
Notes

6 weeks, 22 Hours CE Credits. Required prerequisite for all professional certificates.

fluencetraining.com
2Professional Certificate Programs
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Specialty courses including Psychedelic Harm Reduction and Integration Therapy, Ketamine-Assisted Psychotherapy, and Psilocybin Facilitation. Includes 20% discount when bundled with Essentials course.

fluencetraining.com
3Introduction to Psychedelic Therapy
ModelSubscriptionBilling cadencePay-as-you-go
Notes

12-hour on-demand course for non-clinicians covering MDMA, Psilocybin, Ketamine education.

fluencetraining.com
4Live-Online Webinars with CE Credits
ModelSubscriptionBilling cadencePay-as-you-go
Notes

1 CE hour per webinar. CE credit only available for live attendance.

fluencetraining.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Core offering1 text field

Fluence operates a subscription-based e-learning platform that delivers APA/ASWB/NYSED-accredited continuing education and professional certificate programs in psychedelic therapy to licensed clinicians and psychotherapists, structured as a core Essentials course plus three specialty certificates. The company also generates enterprise revenue from drug developers through an AI-powered clinical trial training platform, custom Learning Management Systems, consultation for protocol design and adherence criteria, and post-launch commercialization services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 8,000+ therapists trained and certified
+2 more records
Product overview1 text field

Fluence is an e-learning education platform providing professional certificate programs in psychedelic therapy for licensed clinicians and healthcare professionals. The platform follows a two-tier curriculum structure: a required Core Curriculum (Essentials of Psychedelic Therapy) followed by three Professional Certificate programs (Psychedelic Harm Reduction and Integration Therapy, Ketamine-Assisted Psychotherapy, and Psilocybin Facilitation). Additional offerings include Introduction to Psychedelic Therapy for non-clinicians, webinars, and free educational content. For drug developers, Fluence offers B2B services including consultation on protocol design, AI-powered clinical trial training with automated feedback, and commercialization support. The platform also provides a Psychedelic Therapist Directory for certified graduates. All professional courses include APA-accredited continuing education credits.

Product and service10 records
1Essentials of Psychedelic Therapy
CategoryCore Curriculum Course
Description

6-week foundational course providing 22 hours of APA-accredited CE credits covering the fundamentals of psychedelic therapy, required as a prerequisite for all Fluence Professional Certificate programs and intended for licensed clinicians.

2Psychedelic Harm Reduction and Integration Therapy Professional Certificate
CategoryProfessional Certificate Program
Description

Specialty professional certificate program for licensed clinicians to gain expertise in harm reduction and integration therapy approaches for psychedelic-assisted treatments; includes CE credits.

3Ketamine-Assisted Psychotherapy Professional Certificate
CategoryProfessional Certificate Program
Description

Specialty professional certificate program focused specifically on ketamine-assisted psychotherapy training for mental health clinicians; includes CE credits.

4Psilocybin Facilitation Professional Certificate
CategoryProfessional Certificate Program
Description

Specialty professional certificate program for clinicians training to facilitate psilocybin-assisted therapy sessions; includes CE credits.

5Introduction to Psychedelic Therapy
CategoryOn-Demand Course
Description

12-hour on-demand introductory course covering molecule-specific education (MDMA, Psilocybin, Ketamine), harm reduction practices, and the fundamentals of psychedelic therapy, designed for non-clinicians seeking personal-interest or general-knowledge training.

6Live-Online Webinars with CE Credits
CategoryLive Educational Events
Description

Live-online webinar series covering psychedelic therapy topics, legislative updates, drug development insights, practice building, and specialized clinical applications, offering 1 CE hour per webinar for clinicians attending live.

7Psychedelic Therapist Directory
CategoryDirectory Service
Description

Verified directory listing service that enables Fluence-certified therapists to be discoverable by clients and industry leaders; displays verifiable digital badges for completed Professional Certificates.

8AI-Powered Clinical Trial Training Platform
CategoryB2B Training Platform
Description

B2B enterprise training platform for drug developers that uses AI-powered transcript analysis to deliver automated adherence feedback on trainee role-play practice sessions, including a custom Learning Management System with role-based access, mobile app access, and timestamped training tracking for clinical trial staff.

9Consultation for Drug Development
CategoryB2B Consulting Service
Description

Clinical research consultation services for drug developers including protocol design, psychedelic treatment manual development, adherence criteria generation, and multinational trial support, delivered by licensed clinicians with psychedelic clinical-trial experience.

10Commercialization Post-Launch Services
CategoryB2B Service
Description

Post-launch support services helping drug developers roll out approved psychedelic treatments, including clinician training, clinic-staff training, patient education materials, and off-label application training programs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership integrating Fluence's AI-powered training tool into Reunion Neuroscience's clinical trials. Reunion is committed to leveraging cutting-edge technologies to enhance the quality and scalability of psychedelic therapy training.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Cybin to integrate Fluence's AI-powered training platform for provider development. Alex Kelman, Ph.D., Head of Therapies at Cybin, noted Fluence's leadership in psychedelic therapy education and technology-based competency development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The leading nonprofit/benefit organization developing MDMA-assisted therapy; directly comparable because it has built standardized therapist training programs and treatment manuals for clinical trials that overlap directly with Fluence's psychedelic therapy curriculum.

TypeBroad incumbent
Description

Public psychedelic drug developer running large psilocybin trials; comparable because it operates (and historically invested in) its own therapist training infrastructure for psilocybin therapy, placing it in direct competition for psychedelic trial training demand.

3Sage Institute
TypeDirect peer
Description

Psychedelic therapy training organization offering clinician certification programs; closely comparable to Fluence in delivering accredited training for ketamine- and psilocybin-assisted therapy practice.

TypeDirect peer
Description

Psychedelic facilitator and therapist training provider offering certificate programs; comparable to Fluence in curriculum structure, clinician audience, and psychedelic-therapy emphasis.

TypeDirect peer
Description

Discovery platform and education provider for psychedelic therapists; comparable to Fluence for its therapist directory and clinician education offerings that compete for the same B2C audience of trained therapists.

TypeDirect peer
Description

Oregon-approved psilocybin facilitator training program that prepares clinicians for state-licensed practice; comparable to Fluence as a direct provider of state/pathway-licensed psychedelic facilitator certification.

7Changa Institute
TypeDirect peer
Description

Psychedelic education and facilitator training provider; comparable to Fluence for its curriculum programs aimed at clinicians seeking psychedelic facilitation credentials.

TypeDirect peer
Description

Ketamine-assisted psychotherapy training center for clinicians; comparable to Fluence because it operates in the same ketamine-assisted psychotherapy training vertical with similar clinician audiences.

TypeBroad incumbent
Description

Large healthcare workforce training and compliance platform serving hospitals and behavioral health providers; comparable to Fluence as a scaled, accredited e-learning incumbent that could expand into psychedelic CE content for clinicians.

10HealthStream
TypeBroad incumbent
Description

Enterprise healthcare workforce development and compliance training platform; comparable to Fluence for its accredited continuing education, regulatory training, and clinical training capabilities targeted at the same clinician buyer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fluence

Professional Training and Continuing Educationfluencetraining.com

Fluence is a New York-based e-learning platform that provides APA/ASWB/NYSED-accredited professional certificates in psychedelic-assisted therapy to licensed clinicians, plus AI-powered clinical trial training and consultation services to drug developers. The company has trained over 8,000 therapists and serves a global client base.

What Fluence does

Fluence operates an e-learning platform that delivers professional certificate programs in psychedelic-assisted therapy and integration for licensed mental health clinicians, alongside continuing education webinars and an introductory on-demand course for non-clinicians. The product architecture centers on a required 22-hour core curriculum, "Essentials of Psychedelic Therapy," that unlocks three specialty professional certificates covering Psychedelic Harm Reduction and Integration Therapy, Ketamine-Assisted Psychotherapy, and Psilocybin Facilitation, each carrying CE credits approved by the APA, ASWB, and NYSED. Fluence wraps the curriculum in proprietary infrastructure including a custom learning management system with role-based access and timestamped training tracking, a digital badging system, and the Psychedelic Therapist Directory, which functions as a marketplace connecting certified graduates with prospective clients and industry partners.

Fluence generates revenue through two distinct streams: individual clinician course sales (multi-year subscription pricing for the core and certificate programs, pay-as-you-go webinars and introductory content, and a 20% bundle discount) and B2B clinical trial training services sold to pharmaceutical and biotech drug developers. The B2B line includes protocol design consultation, treatment manual development, adherence criteria creation, multinational trial support, and the company's AI-powered training platform that uses generative AI to score role-play transcripts against custom rubrics and produce structured feedback. The AI capability is a key differentiator: it has been adopted by named drug developers including Reunion Neuroscience, Cybin, and Tryp Therapeutics, and is built on training data accumulated across over a dozen developer engagements, multiple compounds, and multilingual multinational trial contexts. The company also offers post-launch commercialization support covering clinician training, clinic staff training, and patient education materials.

The company is privately held, headquartered in the Bronx, New York, led by CEO and Co-Founder Elizabeth Nielson, PhD, and has trained over 8,000 therapists cumulatively. It has raised approximately $3 million across a November 2021 seed round ($1.6M from JLS Fund, Palo Santo, and Neo Kuma Ventures) and a February 2022 follow-on ($1.4M). Revenue is not publicly disclosed, but the combination of an 11-50 person headcount, a distributed individual learner base, and a small but growing enterprise B2B book places estimated annual revenue in the low single-digit millions. Strategic positioning centers on being the preeminent credentialing and training infrastructure for both the emerging psychedelic clinician workforce and the drug developers commercializing psychedelic-based treatments.

Fluence firmographics

Firmographics
Name
Fluence
Legal name
Fluence International, Inc.
Website
https://fluencetraining.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Fluence is a New York-based e-learning platform that provides APA/ASWB/NYSED-accredited professional certificates in psychedelic-assisted therapy to licensed clinicians, plus AI-powered clinical trial training and consultation services to drug developers. The company has trained over 8,000 therapists and serves a global client base.
Ownership category
akta.pro rank

Fluence industry classification

Industry
Product category
Professional Training and Continuing Education
NAICS
Professional and Management Development Training (61143)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYEDAGANAJ
Healthcare & Clinical Professional Development (CME/CE)
Education/Educational Publishing & Learning Content/Professional Development & Training Materials

Keywords

  • Psychedelic therapy training
  • Professional certificate programs
  • Continuing education credits
  • Clinical trial training
  • Therapist directory platform

Where Fluence is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Fluence business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Professional Certification Courses: Fluence offers professional certification programs in psychedelic therapy areas including Psychedelic Harm Reduction and Integration Therapy, Ketamine-Assisted Psychotherapy, and Psilocybin Facilitation. All programs include CE credits for psychologists, social workers, and mental health counselors as part of the base price.
  2. B2B Clinical Trial Training Services: Consultation and custom training programs for drug developers including protocol design, treatment manual creation, adherence criteria development, and multinational trial support. Services include custom LMS, mobile apps, content libraries, and differentiated training tracks.
  3. AI-Enabled Training Tools: AI-powered feedback tools for clinical trial training that analyze role-play transcripts and provide automated adherence scoring, offered to drug development partners.
  4. Webinars and Continuing Education: Live-online webinars offering CE credits for clinicians, covering topics in psychedelic therapy, legislation, practice building, and specialized clinical applications.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEssentials of Psychedelic Therapy - Core Curriculum
SubscriptionMulti-year contractProfessional Certificate Programs
SubscriptionPay-as-you-goIntroduction to Psychedelic Therapy
SubscriptionPay-as-you-goLive-Online Webinars with CE Credits

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Fluence product offering

Product offering

Core offering

Fluence operates a subscription-based e-learning platform that delivers APA/ASWB/NYSED-accredited continuing education and professional certificate programs in psychedelic therapy to licensed clinicians and psychotherapists, structured as a core Essentials course plus three specialty certificates. The company also generates enterprise revenue from drug developers through an AI-powered clinical trial training platform, custom Learning Management Systems, consultation for protocol design and adherence criteria, and post-launch commercialization services.

Product overview

Fluence is an e-learning education platform providing professional certificate programs in psychedelic therapy for licensed clinicians and healthcare professionals. The platform follows a two-tier curriculum structure: a required Core Curriculum (Essentials of Psychedelic Therapy) followed by three Professional Certificate programs (Psychedelic Harm Reduction and Integration Therapy, Ketamine-Assisted Psychotherapy, and Psilocybin Facilitation). Additional offerings include Introduction to Psychedelic Therapy for non-clinicians, webinars, and free educational content. For drug developers, Fluence offers B2B services including consultation on protocol design, AI-powered clinical trial training with automated feedback, and commercialization support. The platform also provides a Psychedelic Therapist Directory for certified graduates. All professional courses include APA-accredited continuing education credits.

Differentiator

Problem solved

Functional benefit

Products and services

  • Essentials of Psychedelic Therapy 6-week foundational course providing 22 hours of APA-accredited CE credits covering the fundamentals of psychedelic therapy, required as a prerequisite for all Fluence Professional Certificate programs and intended for licensed clinicians.
  • Psychedelic Harm Reduction and Integration Therapy Professional Certificate Specialty professional certificate program for licensed clinicians to gain expertise in harm reduction and integration therapy approaches for psychedelic-assisted treatments; includes CE credits.
  • Ketamine-Assisted Psychotherapy Professional Certificate Specialty professional certificate program focused specifically on ketamine-assisted psychotherapy training for mental health clinicians; includes CE credits.
  • Psilocybin Facilitation Professional Certificate Specialty professional certificate program for clinicians training to facilitate psilocybin-assisted therapy sessions; includes CE credits.
  • Introduction to Psychedelic Therapy 12-hour on-demand introductory course covering molecule-specific education (MDMA, Psilocybin, Ketamine), harm reduction practices, and the fundamentals of psychedelic therapy, designed for non-clinicians seeking personal-interest or general-knowledge training.
  • Live-Online Webinars with CE Credits Live-online webinar series covering psychedelic therapy topics, legislative updates, drug development insights, practice building, and specialized clinical applications, offering 1 CE hour per webinar for clinicians attending live.
  • Psychedelic Therapist Directory Verified directory listing service that enables Fluence-certified therapists to be discoverable by clients and industry leaders; displays verifiable digital badges for completed Professional Certificates.
  • AI-Powered Clinical Trial Training Platform B2B enterprise training platform for drug developers that uses AI-powered transcript analysis to deliver automated adherence feedback on trainee role-play practice sessions, including a custom Learning Management System with role-based access, mobile app access, and timestamped training tracking for clinical trial staff.
  • Consultation for Drug Development Clinical research consultation services for drug developers including protocol design, psychedelic treatment manual development, adherence criteria generation, and multinational trial support, delivered by licensed clinicians with psychedelic clinical-trial experience.
  • Commercialization Post-Launch Services Post-launch support services helping drug developers roll out approved psychedelic treatments, including clinician training, clinic-staff training, patient education materials, and off-label application training programs.

Quantifiable outcome

  • 8,000+ therapists trained and certified
  • +2 more outcomes

Companies that use Fluence

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Fluence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Fluence partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Reunion NeurosciencecoreStrategic or Co-development PartnerStrategic partnership integrating Fluence's AI-powered training tool into Reunion Neuroscience's clinical trials. Reunion is committed to leveraging cutting-edge technologies to enhance the quality and scalability of psychedelic therapy training.
  • CybincoreStrategic or Co-development PartnerPartnership with Cybin to integrate Fluence's AI-powered training platform for provider development. Alex Kelman, Ph.D., Head of Therapies at Cybin, noted Fluence's leadership in psychedelic therapy education and technology-based competency development.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Fluence competitors and assessment

Company assessment

Direct peers

  • MAPS Public Benefit Corporation: The leading nonprofit/benefit organization developing MDMA-assisted therapy; directly comparable because it has built standardized therapist training programs and treatment manuals for clinical trials that overlap directly with Fluence's psychedelic therapy curriculum.
  • Sage Institute: Psychedelic therapy training organization offering clinician certification programs; closely comparable to Fluence in delivering accredited training for ketamine- and psilocybin-assisted therapy practice.
  • Synthesis Institute: Psychedelic facilitator and therapist training provider offering certificate programs; comparable to Fluence in curriculum structure, clinician audience, and psychedelic-therapy emphasis.
  • Psychedelic.Support: Discovery platform and education provider for psychedelic therapists; comparable to Fluence for its therapist directory and clinician education offerings that compete for the same B2C audience of trained therapists.
  • InnerTrek: Oregon-approved psilocybin facilitator training program that prepares clinicians for state-licensed practice; comparable to Fluence as a direct provider of state/pathway-licensed psychedelic facilitator certification.
  • Changa Institute: Psychedelic education and facilitator training provider; comparable to Fluence for its curriculum programs aimed at clinicians seeking psychedelic facilitation credentials.
  • Polaris Insight Center: Ketamine-assisted psychotherapy training center for clinicians; comparable to Fluence because it operates in the same ketamine-assisted psychotherapy training vertical with similar clinician audiences.

Broad incumbents

  • Compass Pathways: Public psychedelic drug developer running large psilocybin trials; comparable because it operates (and historically invested in) its own therapist training infrastructure for psilocybin therapy, placing it in direct competition for psychedelic trial training demand.
  • Relias: Large healthcare workforce training and compliance platform serving hospitals and behavioral health providers; comparable to Fluence as a scaled, accredited e-learning incumbent that could expand into psychedelic CE content for clinicians.
  • HealthStream: Enterprise healthcare workforce development and compliance training platform; comparable to Fluence for its accredited continuing education, regulatory training, and clinical training capabilities targeted at the same clinician buyer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Fluence social profiles

Digital presence

Fluence compliance and trust

Trust signal

Compliance6 records

Fluence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fluence leadership team

Management profile

Number of profiles

Profiles8 records

Fluence funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fluence M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fluence

What does Fluence do?

Fluence operates a subscription-based e-learning platform that delivers APA/ASWB/NYSED-accredited continuing education and professional certificate programs in psychedelic therapy to licensed clinicians and psychotherapists, structured as a core Essentials course plus three specialty certificates. The company also generates enterprise revenue from drug developers through an AI-powered clinical trial training platform, custom Learning Management Systems, consultation for protocol design and adherence criteria, and post-launch commercialization services.

Is Fluence a public or private company?

Fluence is a private company. It is classified as venture growth investor backed and is currently operating.

When was Fluence founded?

Fluence was founded in 2021. It employs 11 to 50 people.

Where is Fluence based?

Fluence is headquartered in New York, United States, in the North America region.

How does Fluence make money?

Four revenue lines are on record. Professional Certification Courses are the primary driver. The others are B2B Clinical Trial Training Services, AI-Enabled Training Tools and webinars and Continuing Education.

Who are Fluence's main competitors?

Direct peers on record are MAPS Public Benefit Corporation, Sage Institute, Synthesis Institute, Psychedelic.Support, InnerTrek, Changa Institute and Polaris Insight Center. Broad incumbents are Compass Pathways, Relias and HealthStream.

Does Fluence have an API?

No public API is recorded for Fluence.

What industry is Fluence in?

Fluence's product category is Professional Training and Continuing Education. Its primary akta.pro industry code is EDAGANAJ, Healthcare & Clinical Professional Development (CME/CE). Its NAICS code is 61143 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooFluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider TrainingFluence was selected by Compass Pathways to develop a new certificate program training healthcare providers for COMP360 psilocybin treatment, pending FDA approval. The program covers foundational psychedelic care, psilocybin understanding, and COMP360-specific training. Fluence will combine its training expertise with Compass's clinical guidance.Stock TitanFluence Selected by Compass for COMP360 TrainingFluence has been selected by Compass Pathways to develop a post-approval certificate program for clinicians supporting the use of COMP360 psilocybin treatment. The new curriculum, consisting of three modules, aims to prepare healthcare providers with the necessary skills and knowledge if the FDA approves the investigational drug for treatment-resistant depression. This collaboration leverages Fluence's experience in psychedelic therapy education to ensure safe and evidence-based clinical practice.PR NewswireFluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider TrainingFluence was selected by Compass Pathways to develop a new certificate program training healthcare providers for COMP360 psilocybin treatment, if FDA-approved. The program covers foundational psychedelic care, psilocybin understanding, and COMP360-specific training. Fluence will combine its training expertise with Compass's clinical guidance.MorningstarCompass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider TrainingCompass Pathways announced five organizations awarded grants to develop post-approval training for healthcare providers delivering COMP360 psilocybin for treatment-resistant depression. The grants exceed the planned three recipients, with awardees including CME Outfitters, Emory University, and Fluence International. Compass will provide funding while awardees retain independent control of their programs.GlobeNewswirePsyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialPsyence Biomedical, a NASDAQ-listed associate of Psyence Group, partnered with Fluence and iNGENū to support a Phase IIb psilocybin trial. The double-blind study will test three doses in 84 patients, with first enrollment expected in Q2 2024 and primary results in 2025.GlobeNewswirePsyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialPsyence Biomed announced a partnership with Fluence and iNGENū to support a Phase IIb trial of psilocybin-assisted psychotherapy for adjustment disorder in palliative cancer patients. The double-blind, placebo-controlled study will test three doses in 84 patients, with first enrollment expected in Q2 2024 and primary results in 2025.ForbesWar-Torn Ukraine Sees Increased Psychedelic Training To Combat Effects Of PTSDFluence, UPRA, and Heal Ukraine Trauma are partnering to train Ukrainian mental health professionals in psychedelic therapy for PTSD. Over 540 specialists have signed up, and UPRA estimates 3.5 million Ukrainians may develop PTSD from war.JourneyclinicalSXSW Psychedelics Panel w/ Myriam BarthesJourney Clinical co-founder and COO Myriam Barthes participated in an SXSW panel titled "Beyond the Hype: The Business of Psychedelics 2.0" alongside representatives from UC Berkeley Center for Psychedelics, Palo Santo, and Tactogen. Barthes outlined Journey Clinical's collaborative care model that connects therapists with prescribers to deliver ketamine-assisted psychotherapy, noting the company has grown to 700 therapists on its platform. The panel also covered the broader ecosystem supporting psychedelic therapy practitioners, including community building and professional education partnerships with Fluence.PR NewswireTRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIALTryp Therapeutics has dosed the first patient in its Phase II clinical trial for TRP-8802, a psilocybin-based treatment combined with psychotherapy for Binge Eating Disorder, marking what the company calls the world's first FDA-regulated clinical trial for psilocybin-assisted therapy targeting BED. The open-label study, enrolling up to 10 patients, is being conducted in collaboration with the University of Florida and uses psychotherapy protocols developed with Fluence to investigate safety and preliminary efficacy. Tryp is also developing a proprietary formulation, TRP-8803, while utilizing the non-proprietary TRP-8802 for this Phase II study.FinSMEsFluence Raises $3M in Seed FundingFluence, a NYC-based psychedelic therapy training platform, raised $3M in seed funding from JLS Fund, Palo Santo, and Neo Kuma. The company will use the funds to launch new courses, trainings, and certificate programs, and to expand its e-learning platform. It also plans to develop a psilocybin-assisted therapy program for Oregon's Measure 109 implementation.